Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy.

Abstract:

BACKGROUND:Longitudinal assessment of liver fibrosis with transient elastometry (TE) in patients with chronic viral hepatitis is becoming routine clinical practice in many clinics, as this procedure is non-invasive, easy to perform and relatively inexpensive, allowing early detection of cirrhosis. Herein, we examine the incidence of cirrhosis, using TE assessment, in HIV-infected individuals with chronic hepatitis B or C receiving highly active antiretroviral therapy (HAART). METHODS:A longitudinal study was performed on a cohort of HIV-infected patients with chronic hepatitis B or C who were followed since 2004 at Hospital Carlos III (Madrid, Spain) with periodic TE assessments. The primary outcome was the development of cirrhosis, defined as liver stiffness >12.5 KPa. RESULTS:A total of 508 HIV-infected patients were examined, of whom 54 developed liver cirrhosis during a mean ±(SD) follow-up of 2.6 ±1.0 years (overall incidence was 41.13 cases per 1,000 person-years). The risk of developing cirrhosis was significantly higher in 297 HCV-RNA-positive patients (either untreated or non-responders to hepatitis C therapy) compared with 55 patients who had cleared HCV with therapy (odds ratio 3.73, 95% confidence interval 1.06-13.17; P=0.04). By contrast, the risk of developing cirrhosis was low and similar in 24 HIV-HBV-coinfected patients under long-term suppressive HBV therapy (mainly tenofovir disoproxil fumarate), 132 HIV-infected patients without chronic liver disease and those who had cleared HCV with therapy. CONCLUSIONS:Development of liver cirrhosis in HIV-infected individuals in the HAART era is mainly associated with active HCV coinfection. The risk of developing cirrhosis is negligible in patients who cleared HCV with therapy, as well as in HIV-HBV-coinfected patients on long-term suppressive tenofovir disoproxil fumarate therapy.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Tuma P,Medrano J,Resino S,Vispo E,Madejón A,Sánchez-Piedra C,Rivas P,Labarga P,Martín-Carbonero L,Barreiro P,Soriano V

doi

10.3851/IMP1630

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

881-6

issue

6

eissn

1359-6535

issn

2040-2058

journal_volume

15

pub_type

杂志文章
  • Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy.

    abstract:BACKGROUND:Little is known about the prognostic factors of acute liver enzyme variations in HIV-hepatitis B virus (HBV)-coinfected patients. OBJECTIVES:To identify prognostic factors of acute liver enzyme abnormalities in HIV-HBV-coinfected patients with a focus on the putative role of antiretroviral drugs. DESIGN:Da...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Chauvel O,Lacombe K,Bonnard P,Lascoux-Combe C,Molina JM,Miailhes P,Girard PM,Carrat F

    更新日期:2007-01-01 00:00:00

  • External quality assessment of HLA-B*5701 reporting: an international multicentre survey.

    abstract:OBJECTIVES:HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS:DNA pane...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Hammond E,Almeida CA,Mamotte C,Nolan D,Phillips E,Schollaardt TA,Gill MJ,Angel JB,Neurath D,Li J,Giulivi T,McIntyre C,Koultchitski G,Wong B,Reis M,Rachlis A,Cole DE,Chew CB,Neifer S,Lalonde R,Roger M,Jeanneau A

    更新日期:2007-01-01 00:00:00

  • Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir.

    abstract::Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased respo...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1671

    authors: Llibre JM

    更新日期:2010-01-01 00:00:00

  • Drug-drug interactions in HIV therapy: is it all clear?

    abstract::Drug-drug interactions in HIV therapy have been known to the clinic from earliest days of HIV treatment. Hundreds of well-designed pharmacokinetic studies have been performed in either HIV-infected patients or, mostly, in healthy volunteers. Case reports generally are graded lower in terms of evidence-based medicine b...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2688

    authors: Burger D,Back D

    更新日期:2013-01-01 00:00:00

  • Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.

    abstract::The study was carried out to evaluate the therapeutic effects of zanamivir, a highly selective, potent and specific inhibitor of influenza A and B virus neuraminidases, in adult patients with acute influenza-like illness. Patients who presented within 36 h of the onset of influenza-like symptoms were randomly assigned...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Matsumoto K,Ogawa N,Nerome K,Numazaki Y,Kawakami Y,Shirato K,Arakawa M,Kudoh S,Shimokata K,Nakajima S,Yamakido M,Kashiwagi S,Nagatake T

    更新日期:1999-01-01 00:00:00

  • Is there a need for liver disease monitoring in HIV patients in Africa?

    abstract::Liver disease is one of the leading causes of death in HIV-infected individuals from Europe and North America and has been attributed mainly to coinfection with hepatotropic viruses. Little data, however, has so far become available on liver disease in HIV-infected individuals from Africa. Results from a first study o...

    journal_title:Antiviral therapy

    pub_type: 评论,杂志文章

    doi:10.3851/IMP1787

    authors: Rockstroh JK,Peters L,Wedemeyer H

    更新日期:2011-01-01 00:00:00

  • Respiratory viral infections in transplant recipients.

    abstract::A wide range of viruses affect the respiratory tract of transplant recipients, including adenovirus, influenza, human metapneumovirus, parainfluenza virus, respiratory syncytial virus (RSV) and rhinovirus. Prospective studies using contemporary diagnostic techniques have recently improved our understanding of the epid...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Ison MG

    更新日期:2007-01-01 00:00:00

  • Stability of liver fibrosis among HCV-infected injection drug users.

    abstract:BACKGROUND:There are few published data characterizing patterns of liver stiffness measurements (LSMs) among HCV-infected persons and their potential impact on clinical decisions (for example, deferring treatment and hepatocellular carcinoma surveillance). METHODS:A total of 591 HCV-infected injection drug users in a ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2085

    authors: Mehta SH,Kirk GD,Astemborski J,Sulkowski MS,Afdhal NH,Thomas DL

    更新日期:2012-01-01 00:00:00

  • Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).

    abstract:BACKGROUND:Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type and NRTI-resistant viruses. METHODS:ACTG A5118 assessed the antiretroviral activity and safety of DAPD (300 mg orally, twice daily) v...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:

    authors: Gripshover BM,Ribaudo H,Santana J,Gerber JG,Campbell TB,Hogg E,Jarocki B,Hammer SM,Kuritzkes DR,A5118 Team.

    更新日期:2006-01-01 00:00:00

  • The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.

    abstract:BACKGROUND:Antibodies to liver-kidney microsome type 1 (anti-LKM-1), which are a marker of autoimmune hepatitis, are found in a minority of patients with chronic hepatitis C virus (HCV) infection. Whether interferon/ribavirin therapy is safe and effective in these patients is unclear. AIM:To describe the prevalence, c...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Monti V,Aghemo A,Rumi MG,Donato MF,Del Ninno E,Colombo M

    更新日期:2005-01-01 00:00:00

  • Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.

    abstract:BACKGROUND:Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lamb...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Dahari H,Shudo E,Cotler SJ,Layden TJ,Perelson AS

    更新日期:2009-01-01 00:00:00

  • Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia.

    abstract::A 14 year old common variable immunodeficiency patient developed severe protein-losing enteropathy. A chronic enteral infection with human parechovirus type 1 and norovirus was diagnosed. Treatment strategies aimed at virus eradication and providing supportive care were ineffective. The antipicornavirus agent pleconar...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1792

    authors: van de Ven AA,Douma JW,Rademaker C,van Loon AM,Wensing AM,Boelens JJ,Sanders EA,van Montfrans JM

    更新日期:2011-01-01 00:00:00

  • Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.

    abstract:BACKGROUND:Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS:Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Vogel M,Nattermann J,Baumgarten A,Klausen G,Bieniek B,Schewe K,Jessen H,Boesecke C,Rausch M,Lutz T,Fenske S,Schranzo D,Kümmerle T,Schuler C,Theisen A,Mayr C,Seidel T,Rockstroh JK

    更新日期:2006-01-01 00:00:00

  • Transmitted, pre-treatment and acquired antiretroviral drug resistance among men who have sex with men and transgender women living with HIV in Nigeria.

    abstract:BACKGROUND:Across sub-Saharan Africa, men who have sex with men (MSM) and transgender women (TGW) have disproportionately poor HIV treatment outcomes. Stigma and criminalization create barriers to health-care engagement and adherence to antiretroviral therapy (ART), potentially promoting the development of HIV drug res...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3342

    authors: Crowell TA,Kijak GH,Sanders-Buell E,O'Sullivan AM,Kokogho A,Parker ZF,Lawlor J,Polyak CS,Adebajo S,Nowak RG,Baral SD,Robb ML,Charurat ME,Ake JA,Ndembi N,Tovanabutra S,TRUST\/RV368 Study Group.

    更新日期:2019-01-01 00:00:00

  • A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.

    abstract:BACKGROUND:Lamivudine (3TC) therapy can cause the emergence of M1841/V. Previous studies suggest a higher fidelity of the mutant reverse transcriptase and lower replication capacity of the mutant virus. No data exist from clinical comparative studies evaluating the benefit of M1841/V in patients receiving combination a...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:

    authors: Fox Z,Dragsted UB,Gerstoft J,Phillips AN,Kjaer J,Mathiesen L,Youle M,Katlama C,Hill A,Bruun JN,Clumeck N,Dellamonica P,Lundgren JD,COLATE study group.

    更新日期:2006-01-01 00:00:00

  • Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.

    abstract:BACKGROUND:Monocytes transmigrating to the brain play a central role in HIV neuropathology. We hypothesized that the continued existence of neurocognitive impairment (NCI) despite potent antiretroviral (ARV) therapy is mediated by the inability of such therapy to control this monocyte/macrophage reservoir. METHODS:Cro...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2411

    authors: Shikuma CM,Nakamoto B,Shiramizu B,Liang CY,DeGruttola V,Bennett K,Paul R,Kallianpur K,Chow D,Gavegnano C,Hurwitz SJ,Schinazi RF,Valcour VG

    更新日期:2012-01-01 00:00:00

  • Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients.

    abstract:BACKGROUND:This study aimed to evaluate whether low darunavir (DRV) minimum plasma concentration (Cmin) values contribute to virological outcomes during DRV/ritonavir monotherapy (mtDRV/rtv). METHODS:This was a prospective observational single-arm 96-week efficacy study in virologically suppressed subjects on triple t...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2722

    authors: Gutierrez-Valencia A,Torres-Cornejo A,BenMarzouk-Hidalgo OJ,Ruiz-Valderas R,Lluch A,Viciana P,López-Cortés LF

    更新日期:2014-01-01 00:00:00

  • Preventing and treating secondary bacterial infections with antiviral agents.

    abstract::Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data, but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1730

    authors: McCullers JA

    更新日期:2011-01-01 00:00:00

  • Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.

    abstract::HIV-HBV-coinfected patients require optimal control of viral replication in order to prevent the development of severe comorbidities, such as liver cirrhosis and hepatocellular carcinoma. The genetic diversity of HBV is a poorly investigated factor of such viral replication in HIV-infected hosts. HBV genome diversity ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1495

    authors: Lacombe K,Boyd A,Gozlan J,Lavocat F,Girard PM,Zoulim F

    更新日期:2010-01-01 00:00:00

  • Antiviral activity of FNC, 2'-deoxy-2'-β-fluoro-4'-azidocytidine, against human and duck HBV replication.

    abstract:BACKGROUND:New drugs are needed to combat HBV infection. We investigated the anti-HBV activity of the deoxycytidine analogue FNC, which has anticancer activity and has been found to inhibit HCV replication. METHODS:In this study, a human hepatoma HepG2.2.15 cell culture system and duck HBV (DHBV) infection model were ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2094

    authors: Zheng L,Wang Q,Yang X,Guo X,Chen L,Tao L,Dong L,Li Y,An H,Yu X,Wang Q,Chang J

    更新日期:2012-01-01 00:00:00

  • Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study.

    abstract::Oseltamivir phosphate is an FDA-approved treatment for influenza that has been available for prescription use in the USA since 1999. The present report describes findings from a post-marketing safety study of skin reactions associated with oseltamivir use. All patients in the claims-derived Ingenix Research Database w...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Nordstrom BL,Oh K,Sacks ST,L'Italien GJ

    更新日期:2004-04-01 00:00:00

  • Clinically relevant drug interactions with antiretroviral agents.

    abstract::With the advent of the human immunodeficiency virus (HIV) protease inhibitors and the non-nucleoside reverse transcriptase inhibitors, the importance of drug-drug interactions with antiretroviral agents is becoming increasingly recognized. Every clinician involved in the care of HIV-infected persons should have a broa...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Burger DM,Hoetelmans RM,Koopmans PP,Meenhorst PL,Mulder JW,Hekster YA,Beijnen JH

    更新日期:1997-07-01 00:00:00

  • Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.

    abstract:BACKGROUND:A genome-wide association study revealed an association between variants of the inosine triphosphatase (ITPA) gene and ribavirin (RBV)-induced anaemia. The aim of this study was to replicate this finding in an independent Japanese cohort and to define a method to allow pretreatment prediction of anaemia in c...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1796

    authors: Kurosaki M,Tanaka Y,Tanaka K,Suzuki Y,Hoshioka Y,Tamaki N,Kato T,Yasui Y,Hosokawa T,Ueda K,Tsuchiya K,Kuzuya T,Nakanishi H,Itakura J,Takahashi Y,Asahina Y,Matsuura K,Sugauchi F,Enomoto N,Nishida N,Tokunaga K,Miz

    更新日期:2011-01-01 00:00:00

  • Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals.

    abstract:BACKGROUND:The increased risk for cardiovascular disease (CVD) in HIV is well established. Despite high prevalence of viral hepatitis coinfection with HIV, there are few studies on the risk of CVD amongst antiretroviral therapy (ART)-treated coinfected patients. METHODS:Ontario HIV Treatment Network Cohort Study parti...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2724

    authors: Gillis J,Smieja M,Cescon A,Rourke SB,Burchell AN,Cooper C,Raboud JM,OHTN Cohort Study Group.

    更新日期:2014-01-01 00:00:00

  • Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.

    abstract:BACKGROUND:US guidelines recommend genotyping for persons newly diagnosed with HIV infection to identify transmitted drug resistance mutations associated with decreased susceptibility to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors. To date, testin...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2780

    authors: Stekler JD,McKernan J,Milne R,Tapia KA,Mykhalchenko K,Holte S,Maenza J,Stevens CE,Buskin SE,Mullins JI,Frenkel LM,Collier AC

    更新日期:2015-01-01 00:00:00

  • Increased CD34+/KDR+ cells are not associated with carotid artery intima-media thickness progression in chronic HIV-positive subjects.

    abstract:BACKGROUND:Endothelial progenitor cells (EPCs) are involved in the endothelium repair. Low circulating EPC levels are predictive of cardiovascular events in HIV-negative subjects. The impact of HIV infection on EPCs, and the role of EPCs in HIV-associated cardiovascular disease, is not known. We hypothesized that circu...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2013

    authors: Papasavvas E,Hsue P,Reynolds G,Pistilli M,Hancock A,Martin JN,Deeks SG,Montaner LJ

    更新日期:2012-01-01 00:00:00

  • Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

    abstract::Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Nolan D,John M,Mallal S

    更新日期:2001-09-01 00:00:00

  • HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.

    abstract:BACKGROUND:In pregnant women taking antiretroviral treatment at conception treatment may be transiently stopped for safety concerns. Limited data are available on the consequences of such discontinuations. METHODS:We used data from a national study to compare different treatment pathways during pregnancy. Overall, 321...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Tamburrini E,Ravizza M,Floridia M,Tibaldi C,Alberico S,Anzidei G,Maccabruni A,Meloni A,Antoni AD,Mori F,Dalzero S,Conservan V,Pinnetti C,Ferrazzi E,Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

    更新日期:2008-01-01 00:00:00

  • Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.

    abstract:BACKGROUND:Acute exacerbation (AE) in chronic hepatitis B (CHB) is usually followed by a spontaneous decline in HBV DNA levels. The subsequent treatment is controversial. In this study, we evaluated the efficacy and safety of pegylated interferon-α2a (PEG-IFN-α2a) for such CHB patients. METHODS:A total of 74 hepatitis...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2832

    authors: Cai Q,Chen F,Shao X,Zhang X,Zhao Z,Gao Z

    更新日期:2015-01-01 00:00:00

  • Altered heterochromatin organization after perinatal exposure to zidovudine.

    abstract:BACKGROUND:Zidovudine (3'-azido-3'-deoxythymidine, AZT), administered to pregnant women alone or in combination with other antiretroviral drugs, greatly reduces the mother-to-child transmission of HIV-1. The potential genotoxicity of these molecules is underestimated and wide-ranging evaluation of its biological and cl...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Senda S,Blanche S,Costagliola D,Cibert C,Nigon F,Firtion G,Floch C,Parat S,Viegas-Péquignot E

    更新日期:2007-01-01 00:00:00